2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.18 Dasilva

PP01.18 Dasilva - Poster

Pdf Summary

The document discusses the safety and clinical activity of PT-112, a novel drug for treating recurrent thymoma and thymic carcinoma, both rare cancers with limited treatment options. PT-112 works by inducing immunogenic cell death and stimulating an anti-cancer immune response. A phase II trial showed promising early signs of clinical activity and tolerability in participants with these tumors. The most common treatment-related side effects were anemia, thrombocytopenia, fatigue, and peripheral neuropathy. Notably, some participants experienced a relapse of autoimmune conditions, but no new immune-related adverse events were observed.<br /><br />The study also included immune analyses of blood and tumor tissue, showing increased tumor immune cell infiltration after PT-112 treatment. Changes in serum analytes indicated immune activation, with increased pro-inflammatory markers and a decrease in immune suppressive factors. Survival analysis revealed a median progression-free survival of 15 months for thymoma and 6.1 months for thymic carcinoma, with an overall survival rate of 100% at 6 months for both types of tumors.<br /><br />The document presents figures illustrating CT scans, survival analysis, immune cell infiltration in tumor tissue, and changes in serum analytes. The study is ongoing, aiming to evaluate the efficacy of PT-112 in patients with these rare tumors. Overall, PT-112 shows potential as a new therapeutic option for patients with recurrent thymoma and thymic carcinoma, holding promise for improved treatment outcomes in this challenging clinical scenario.

Keywords

PT-112

thymoma

thymic carcinoma

immunogenic cell death

anti-cancer immune response

phase II trial

treatment-related side effects

immune analyses

progression-free survival

immune cell infiltration